Monitoring Visits

9,885 views

Published on

Introduces to the types of Mnitoring Visits and duties to be performed by Clinical Research Associates during each Visit.

Published in: Business, Technology

Monitoring Visits

  1. 1. Monitoring Visits Jobin Kunjumon Vilapurathu
  2. 2. DefinitionMonitoring The act of overseeing the progress of a clinical trial, and of ensuring that it is conducted, recorded, and reported in accordance with the protocol, SOPs, GCP, & the applicable regulatory requirements.Monitoring Report A written report from the monitor to the sponsor after each site visit and other trial-related communication according to the sponsor’s SOPs.
  3. 3. Purpose The rights & well being of the human subjects are protected . The reported trial data are accurate ,complete and verifiable from source documents. The conduct of the trial is in compliance with the currently approved protocol or amendments, with GCP & with applicable regulatory requirements.
  4. 4. FrequencyFrequency of monitoring visits is not defined by ICH or FDA regulations ICH states that “the sponsor should ensure trials are adequately monitored before, during and after the study”. The frequency of monitoring depends on ◦ The complexity of the study ◦ Rate of enrollment ◦ GCP compliance issues
  5. 5. Selection & Qualification of monitors Should be appointed by the sponsor. Should be appropriately trained & should have scientific/clinical knowledge. Qualification should be documented. Should be thoroughly familiar with the IP, protocol, ICF, & any other written information to be provided to subjects, the SOPs, GCP & applicable regulatory requirements.
  6. 6. TypesThe most common types of site visits for industry-sponsored studies: ◦ Site Evaluation/Qualification Visit ◦ Site Initiation Visit ◦ Site Monitoring Visit ◦ Site Close-Out Visit
  7. 7. Site Evaluation VisitICH Guidelines nor FDA regulations specifically require a SiteEvaluation Visit.ICH does require a pre-trial monitoring report as part of the“Essential Documents” and states that there is a need for on-sitemonitoring “before, during and after” a trial.FDA “Guidelines for the Monitoring of Clinical Investigations”does recommend that a monitor visit the site of the clinicalinvestigation prior to the initiation of the trial.
  8. 8. Site Evaluation Visit Investigator’s Qualifications: 1. Up-to-date CV 2. Specialty 3. Previous experience in conducting trial. Adequate Resources: 1.Retrospective data 2.Sufficient time 3.Adequate number of qualified staff
  9. 9. Site Evaluation Visit Adequate facilities: 1.Exam rooms 2.Pharmacy/Study drug storage area 3.Laboratory or specimen processing area 4.Special testing areas ( x-rays, CT scans, endoscopy, etc.) 5.Record keeping facilities
  10. 10. Site Evaluation Visit Protocol review/discussion ◦ Study objectives ◦ Inclusion/exclusion criteria  Are there barriers to enrollment at your site? ◦ Study Procedures/Tests  Can you perform all the procedures/tests required for the study? ◦ Schedule of Assessments  Special considerations such as weekend/24 hour coverage, etc. ◦ Are there any competing trials?
  11. 11. Site Initiation Visit The purpose of the SIV is to assists the site in its preparation to enroll its first subject & should take place after all required supplies are at the site and just before subject recruitment begins. ICH GCP does require a Trial Initiation Monitoring report as part of the “Essential Documents” and the report should be in both the sponsor and site file. FDA Guidelines recommend that a monitoring visit should take place “shortly” after the site has enrolled its first few subjects if an SIV was not conducted.
  12. 12. Site Monitoring VisitICH 5.1.8.4, Monitor’s Responsibilities Acting as the main line of communication between the sponsor and the investigator. Verifying that the investigator has adequate qualifications and resources throughout the study. Verifying that the investigational product is stored, dispensed and returned properly and that only eligible subjects receive it at the protocol specified dose. Verifying that the investigator follows the approved protocol/amendments.
  13. 13. Site Monitoring Visit Verifying that written informed consent was obtained before each subject’s participation in the trial. Ensuring that the investigator receives the current Investigator’s Brochure and safety updates. Ensuring that the investigator and the investigator’s staff are adequately informed about the trial. Verifying that the investigator is enrolling only eligible subjects.
  14. 14. Site Monitoring Visit Verifying that the investigator and the investigator’s trial staff are performing the specified trial functions, in accordance with the protocol, and have not delegated these functions to unauthorized staff. Reporting the subject recruitment rate. Verifying that source documents and other trial records are accurate, complete and up-to-date.
  15. 15. Site Monitoring Visit Informing the investigator of any CRF entry error, omission or illegibility. The monitor should ensure that appropriate corrections, additions or deletions are made, dated, explained (if necessary) and initialed by the investigator or a trial staff member that has been authorized to make CRF changes for the investigator. This authorization should be documented. Determining whether the investigator is maintaining the essential documents.
  16. 16. Site Monitoring Visit Determining whether all adverse events are appropriately reported within the time periods required by GCP, the protocol, the IRB, the sponsor and the applicable regulatory authorities. Communicating deviations from the protocol, SOPs and GCP to the investigator and taking appropriate action designed to prevent recurrence of the deviations.
  17. 17. Monitoring ReportMonitor submits to the sponsor after each trial site visit:o Written report.o Should include date, site, name of the monitor, investigator or other individuals contacted.o Summary of what the monitor reviewed & the monitor’s statements concerning significant findings/facts, deviations & deficiencies, conclusions, actions taken or to be taken &/actions recommended to secure compliance.o Review & follow-up of the report with the sponsor should be documented by sponsor’s designated representative.
  18. 18. Site Close-Out VisitThere are no clear ICH or FDA regulations regarding the close- out visit.ICH GCP requires a close-out monitoring report as an Essential Document.In general, three activities are required to “officially” close-out a site. ◦ The sponsor conducts a close-out visit and signs the monitoring log. ◦ The investigator submits a final report to the IRB stating that the site is closed. ◦ The sponsor sends the investigator a letter stating that the site is closed.
  19. 19. Site Close-Out VisitClose-Out Visit Activities ◦ Final data review/collection of all outstanding data ◦ Return or destruction of all study drug ◦ Final review of Regulatory Binder ◦ Verification that all biological samples have been submitted
  20. 20. Site Close-Out Visit ◦ Return or destruction of all unused study forms/CRFs ◦ Review and collection of Delegation of Authority forms ◦ Collection of IRB closure report/letter

×